<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2000
Commission file number 0-22332
INSITE VISION INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE 94-3015807
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
965 ATLANTIC AVENUE
ALAMEDA, CA 94501
(Address of Principal Executive Offices, including Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (510) 865-8800
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
The number of shares of Registrant's common stock, $.01 par value,
outstanding as of March 31, 2000: 21,083,877.
<PAGE> 2
QUARTERLY REPORT ON FORM 10-Q
FOR THE THREE MONTHS ENDED MARCH 31, 2000
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C> <C>
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets at
March 31, 2000 and December 31, 1999............................. 3
Condensed Consolidated Statements of Operations
For the three months ended March 31, 2000 and 1999............... 4
Condensed Consolidated Statements of Cash Flows
For the three months ended March 31, 2000 and 1999............... 5
Notes to Condensed Consolidated Financial Statements ........... 6
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations.................... 7
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
Exhibits ....................................................... 16
Reports on Form 8-K......................................................... 16
</TABLE>
2 of 16
<PAGE> 3
PART I FINANCIAL INFORMATION
ITEM 1. Financial Statements
INSITE VISION INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
<TABLE>
<CAPTION>
March 31, December 31,
(in thousands, except share and per share amounts) 2000 1999
- ---------------------------------------------------------------------------------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 9,332 $ 6,746
Prepaid expenses and other current assets 996 598
-------- --------
Total current assets 10,328 7,344
Property and equipment, at cost:
Laboratory and other equipment 284 204
Leasehold improvements 10 10
-------- --------
294 214
Accumulated depreciation 109 95
-------- --------
185 119
-------- --------
Total assets $ 10,513 $ 7,463
======== ========
LIABILITIES, REDEEMABLE PREFERRED STOCK AND COMMON
STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 171 $ 119
Deferred cost recovery 1,632 -
Accrued liabilities 415 534
Accrued compensation and related expense 515 524
Current portion of capital lease obligation 7 -
-------- --------
Total current liabilities 2,740 1,177
Capital lease obligation, less current portion 31 -
Commitments
Redeemable preferred stock, $0.01 par value, 5,000,000 31 30
shares authorized; no shares issued and outstanding
at March 31, 2000 and December 31, 1999
Common stockholders' equity:
Common stock, $0.01 par value, 30,000,000 shares
authorized; 21,083,877 issued and outstanding at
March 31, 2000; 20,298,923 issued and
outstanding at December 31, 1999 211 203
Additional paid-in-capital 92,987 90,807
Accumulated deficit (85,487) (84,754)
-------- --------
Common stockholders' equity 7,711 6,256
-------- --------
Total liabilities, redeemable preferred stock and common
stockholders' equity $ 10,513 $ 7,463
======== ========
</TABLE>
See accompanying notes to condensed consolidated financial statements.
3 of 16
<PAGE> 4
INSITE VISION INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
Three months ended March 31,
(in thousands, except per share amounts) 2000 1999
- -----------------------------------------------------------------------------
<S> <C> <C>
Royalty revenues $ 6 $ 7
Operating expenses:
Research and development, net 244 455
General and administrative 576 638
-------- --------
Total 820 1,093
-------- --------
Loss from operations (814) (1,086)
Interest, other income and expense 82 12
-------- --------
Net loss (732) (1,074)
Non-cash preferred dividends 1 12
-------- --------
Net loss applicable to common stockholders $ (733) $ (1,086)
======== ========
Basic and diluted net loss per share
applicable to common stockholders $ (0.03) $ (0.06)
======== ========
Shares used to calculate basic and
diluted net loss per share 21,058 18,261
======== ========
No cash dividends were declared or paid
during the periods.
</TABLE>
See accompanying notes to condensed consolidated financial statements.
4 of 16
<PAGE> 5
INSITE VISION INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
Three months ended March 31,
(in thousands) 2000 1999
- ---------------------------------------------------------------------------------------
<S> <C> <C>
OPERATING ACTIVITIES
Net loss $ (732) $(1,074)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 82 196
Changes in:
Prepaid expenses and other current assets (398) 1
Accounts payable and accrued liabilities 1,556 96
------- -------
Net cash provided by (used in) operating activities 508 (781)
INVESTING ACTIVITIES
Purchases of property and equipment (43) (12)
------- -------
Net cash used in investing activities (43) (12)
FINANCING ACTIVITIES
Issuance of common stock 2,122 2,000
Payment of capital lease obligation 1 -
------- -------
Net cash provided by financing activities 2,121 2,000
Net increase in cash and cash equivalents 2,586 1,207
Cash and cash equivalents, beginning of period 6,746 1,037
------- -------
Cash and cash equivalents, end of period $ 9,332 $ 2,244
======= =======
Supplemental disclosures:
Non-cash preferred dividends $ 1 $ 12
======= =======
Non-cash conversion of redeemable
preferred stock to common stock $- $ 828
======= =======
Capital lease obligation incurred $ 39 $-
======= =======
</TABLE>
See accompanying notes to condensed consolidated financial statements.
5 of 16
<PAGE> 6
INSITE VISION INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2000
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements
have been prepared in accordance with generally accepted accounting principles
for interim financial information pursuant to the instructions to Form 10-Q and
Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. In the opinion of management, all
adjustments, consisting of normal recurring adjustments, considered necessary
for a fair presentation have been included. Operating results for the three
month period ended March 31, 2000, are not necessarily indicative of the results
that may be expected for any future period.
These financial statements and notes should be read in conjunction with
the Company's audited financial statements and notes thereto included in the
Company's Annual Report on Form 10-K for the year ended December 31, 1999.
NOTE 2 - DEFERRED COST RECOVERY
In January 2000, the Company received $2.0 million from Pharmacia
Corporation (Pharmacia) pursuant to the November 1999, ISV-900 Project
Agreement, to be used to reimburse the Company for costs incurred in support of
the ISV-900 project. As of March 31, 2000, $1.6 million of these funds were
included in current liabilities as deferred cost recovery. The Company directly
reduces expenses for amounts reimbursed pursuant to cost sharing agreements.
During the first quarter of 2000 and 1999, research and development expenses
were reduced by $1.2 million and $0.9 million, respectively, for costs
reimbursed by Pharmacia pursuant to ISV-205 and ISV-900 agreements.
NOTE 3 - SUBSEQUENT EVENTS - STOCKHOLDERS' EQUITY
In May 2000, the Company received net proceeds of $13.0 million from a
private placement of 3,349,722 shares of its common stock and warrants to
purchase an additional 1,172,381 shares of common stock. The warrants entitle
their holder to purchase shares of the Company's common stock for $5.64 from
August 30, 2000 until May 2004. In April 2000, the Company received $625,000
from the issuance of 192,308 shares of its common stock from the exercise of
warrants issued in January 1996.
6 of 16
<PAGE> 7
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion should be read in conjunction with the
financial statements and notes thereto included in this Quarterly Report and in
the Company's Annual Report on Form 10-K for the year ended December 31, 1999.
Except for the historical information contained herein, the discussion
in this Quarterly Report may contain certain forward-looking statements, such as
statements of the Company's plans, objectives, expectations and intentions, that
involve risks and uncertainties. The cautionary statements made in this
Quarterly Report, including those set forth below under the heading "Risk
Factors," should be read as being applicable to all relevant forward-looking
statements wherever they appear in this Quarterly Report. The Company's actual
results could differ materially from those discussed herein.
OVERVIEW
InSite Vision Incorporated ("InSite," "InSite Vision" or the "Company")
is developing genetically-based tools for the diagnosis, prognosis and
management of glaucoma and ophthalmic pharmaceutical products based on its
proprietary DuraSite(R) eyedrop-based drug delivery technology.
The Company is focusing its research and development on (i) expansion of
the ISV-900 technology for the prognosis, diagnosis and management of glaucoma,
(ii) providing on-going technical support to Pharmacia for ISV-205 for the
treatment of inflammation and the prevention and treatment of glaucoma, (iii)
ISV-615 for the treatment of diabetic retinopathy and macular degeneration, (iv)
ISV-014, a retinal drug delivery device, and (v) evaluation and development of
several antibiotics not currently used in ophthalmics.
The Company is collaborating with academic researchers to develop new
diagnostic, prognostic and management tools for primary congenital, juvenile and
primary open angle glaucomas. Primary congenital glaucoma is an inherited eye
disorder and is one of the leading causes of blindness and visual impairment
affecting infants. A gene-based diagnostic kit may allow early detection of the
disease before considerable irreversible damage has occurred and may improve the
ability to treat it successfully. Primary open angle glaucoma usually affects
people over the age of forty. Current glaucoma tests are generally unable to
detect the disease before substantial damage to the optic nerve has occurred.
Gene-based tests may make it possible to identify patients at risk and initiate
treatment before permanent optic nerve damage and vision loss occurs.
The Company has international and U.S. collaborations with academic
institutions for the identification and clinical evaluation of genetic markers
for glaucoma. To date, the Company's academic collaborators at the University of
California, San Francisco ("UCSF") and the University of Connecticut Health
Center ("UCHC") have identified genes associated with primary open-angle
glaucoma (the most prevalent form of the disease in adults), juvenile glaucoma
and primary congenital glaucoma. A diagnostic/prognostic technology, ISV-900,
which is capable of identifying multiple glaucoma genetic markers from a single
sample, has been developed and, in November 1999, the Company licensed the
technology to Pharmacia.
Another result of the glaucoma genetics research has been the
development of the ISV-205 product candidate. This DuraSite formulation contains
a drug that has been shown in cell and organ culture systems to inhibit the
production of a protein that appears to cause glaucoma. In January 1999, the
Company entered into a transaction that granted Pharmacia an exclusive worldwide
license for ISV-205 for the treatment of glaucoma. In June 1999, the Company
announced positive results from its Phase II trial of ISV-205. Pharmacia has
assumed continued development of the product with continued technical support of
the Company.
Ophthalmic conditions that involve retinal damage include macular
degeneration, which affects 10 million or more people in the U.S., and diabetic
retinopathy, a common side effect of diabetes. Approximately ten to fourteen
million people in the U.S. are diabetics. Both macular degeneration and diabetic
retinopathy can lead to irreversible vision loss and blindness. Current
treatment of retinal diseases generally involves surgery and laser treatments
that can lead to loss of vision, retinal detachment and infection. There is no
effective drug therapy for these conditions.
ISV-615 is a DuraSite-based ophthalmic formulation of batimastat that
the Company is evaluating for its potential in preventing neovascularization in
the retina related to diabetic retinopathy and macular degeneration. The Company
obtains batimastat, the active ingredient of ISV-615, through a 1992 agreement
with British Biotech Pharmaceuticals Limited ("British Biotech"), which in
December 1996 advised the Company that it had discontinued
7 of 16
<PAGE> 8
development and manufacturing of batimastat. The Company and British Biotech are
in negotiations on a new licensing agreement related to batimastat that provides
for continued supply of the drug. See "Risk Factors - Dependence on Third
Parties."
Another technology platform is comprised of a device, ISV-014, for the
controlled, non-surgical delivery of ophthalmic drugs to the retina and
surrounding tissues. The Company is continuing to enhance the device and is
collaborating with various academic researchers to perform invivo experiments
delivering products with a variety of molecular sizes to retinal tissues. The
combination of this device technology with polymer-based drug platforms may
permit long term delivery of therapeutic agents to treat several retinal
diseases, most of which cannot be effectively treated at the present time.
ISV-401 is a formulation of an antibiotic that has not previously been
used in ophthalmology. The antibiotic, which is effective both for gram-negative
and gram-positive bacteria, may also provide reduced dosing frequency. Current
ophthalmic antibiotics must be dosed every two hours during the first day and
four times a day for the remainder of the treatment period, which may be up to
fourteen days. This may result in patient compliance issues that could be
minimized with an improved product. Also, a broad-spectrum antibiotic could be
used by physicians to treat a variety of ophthalmic diseases instead of
targeting each disease specifically.
The DuraSite delivery system is a patented eyedrop formulation
comprising a cross-linked carboxyl-containing polymer which incorporates the
drug to be delivered to the eye. The formulation is instilled in the cul-de-sac
of the eye as a small volume eyedrop. DuraSite can be customized to deliver a
wide variety of potential drug candidates with a broad range of molecular
weights and other properties. The DuraSite formulation remains in the eye for up
to several hours during which time the active drug ingredient is gradually
released. DuraSite extends the residence time of the drug due to a combination
of mucoadhesion, surface tension and viscosity. Eyedrops delivered in the
DuraSite system contrast to conventional eyedrops which typically only last in
the eye a few minutes, thus requiring delivery of a highly concentrated burst of
drug and frequent administration to sustain therapeutic levels. The increased
residence time for DuraSite is designed to permit lower concentrations of a drug
to be administered over a longer period of time, thereby minimizing the
inconvenience of frequent dosing and reducing the potential related adverse side
effects.
To date, InSite Vision has not received any revenues from the sale of
products, although it has received a small amount of royalties from the sale of
products using the Company's licensed technology. Until 1999, the Company had
been unprofitable since its inception due to continuing research and development
efforts, including preclinical studies, clinical trials and manufacturing of its
product candidates. The Company has financed its research and development
activities and operations primarily through private and public placement of its
equity securities and, to a lesser extent, from collaborative agreements.
As of March 31, 2000, the Company's accumulated deficit was
approximately $85.5 million. There can be no assurance that InSite Vision will
ever achieve either significant revenues or profitable operations.
RESULTS OF OPERATIONS
The Company earned revenues of $6,000 in the first quarter of 2000, from
sales of AquaSite by CIBA Vision and certain key components of AquaSite to Kukje
Pharma Ind. Co., Ltd., the Company's AquaSite manufacturing partner in Korea.
The Company earned $7,000 in the first quarter of 1999, from sales of AquaSite
by CIBA Vision. To date, the Company has not relied on such revenues to fund its
activities.
Research and development expenses, net, decreased to $244,000 from
$455,000 for the first quarter of 2000 compared to the first quarter of 1999.
This reflects reimbursement from Pharmacia pursuant to the January 1999, ISV-205
and November 1999, ISV-900 licensing agreements, of research expenses of
$1,201,000 and $900,000 in the first quarter of 2000 and 1999, respectively. The
increase in the amount reimbursed primarily reflects cost recovery beginning in
the first quarter of 2000 for the ISV-900 program expenses.
General and administrative expenses decreased 10% from $638,000 during
the first quarter of 1999 to $576,000 during the first quarter of 2000. This
decrease was primarily due to legal and consulting costs, mainly related to
licensing activities, incurred in the first quarter of 1999.
8 of 16
<PAGE> 9
Net interest and other income was $82,000 and $12,000 in the first
quarter of 2000 and 1999, respectively. These fluctuations are due principally
to changes in average cash balances. Interest earned in the future will be
dependent on the Company's funding cycles and prevailing interest rates.
The Company incurred net losses applicable to common stockholders of
$733,000 and $1.1 million during the first quarter of 2000 and 1999,
respectively. The decrease for the first quarter of 2000 compared to 1999 was
due primarily to the reimbursement of research expenses by Pharmacia, pursuant
to the Company's ISV-900 project. The Company may incur substantial additional
losses over the next several years. These losses are expected to fluctuate from
period to period based primarily on the level of the Company's product
development and clinical activities and the level of third-party reimbursement
and milestone payments received by the Company.
LIQUIDITY AND CAPITAL RESOURCES
Through 1995, InSite Vision financed its operations primarily through
private placements of preferred stock, totaling approximately $32 million, and
an October 1993 public offering of Common Stock, which resulted in net proceeds
of approximately $30 million. After 1995, the Company financed its operations
primarily through a January 1996 private placement of Common Stock and warrants
resulting in net proceeds of approximately $4.7 million and an April 1996 public
offering which raised net proceeds of approximately $8.1 million. In accordance
with a July 1996 agreement between the Company and Bausch & Lomb
Pharmaceuticals, Inc. (B&L), the Company received a total of $2.0 million from
the sale of Common Stock in August 1996 and 1997. In September 1997, the Company
completed a $7.0 million private placement of 7,000 shares of Series A
Redeemable Convertible Preferred Stock (Series A preferred stock) for which net
proceeds were approximately $6.5 million. In January 1999, the Company entered
into a transaction with Pharmacia from which the Company received a total of
$3.5 million from the sale of Common Stock in January 1999 and September 1999.
In November 1999, the Company entered into another transaction with Pharmacia
from which the Company received a $5.0 million licensing fee and, in January
2000, received $2.0 million from the sale of 723,195 shares of Common Stock.
Subsequent to the end of the first quarter of 2000, the Company received
$625,000 from the issuance of Common Stock from the exercise of warrants issued
as part of the January 1996 private placement. In May 2000, the Company
completed a private placement of Common Stock and warrants resulting in net
proceeds of approximately $13.0 million.
At March 31, 2000, the Company had cash and cash equivalents totaling
$9.3 million compared to $6.7 million as of December 31, 1999. It is the
Company's policy to invest these funds in highly liquid securities, such as
interest bearing money market funds, Treasury and federal agency notes and
corporate debt.
The increase in net cash provided by operating activities of $508,000 in
the three months ended March 31, 2000 from December 31, 1999, related primarily
to a transaction with Pharmacia. In January 2000, the Company received $2.0
million from Pharmacia pursuant to the ISV-900 Project Agreement, to be used to
reimburse the Company for costs incurred in support of the ISV-900 project. As
of March 31, 2000, $1.6 million of these funds were included in accounts payable
and accrued liabilities as deferred cost recovery. The $398,000 change in
prepaid expenses and other current assets was primarily due to the increase in
the receivable from Pharmacia for technical support provided pursuant to the
ISV-205 License Agreement.
The Company purchased $43,000 of laboratory and other equipment in the
first quarter of 2000 compared with $12,000 in the first quarter of 1999. The
Company also entered into a $39,000 capital lease for certain laboratory
equipment.
The Company received $2.0 million from the issuance of Common Stock to
Pharmacia pursuant to the November 1999 Stock Purchase Agreement. In addition,
the Company received $122,000 from the issuance of Common Stock from the
exercise of stock options by employees.
The Company's future capital expenditures and requirements will depend
on numerous factors, including the progress of its research and development
programs and preclinical and clinical testing, the time and costs involved in
obtaining regulatory approvals, the ability of the Company to establish
additional collaborative arrangements, the cost of filing, prosecuting,
defending and enforcing patent claims and other intellectual property rights,
competing technological and market developments, changes in the Company's
existing collaborative and licensing relationships, acquisition of new
businesses, products and technologies, the completion of commercialization
activities and arrangements, and the purchase of additional property and
equipment.
The Company anticipates no material capital expenditures to be incurred
for environmental compliance in fiscal year 2000. Based on the Company's good
environmental compliance record to date, and its current compliance with
applicable environmental laws and regulations, environmental compliance is not
expected to have a material adverse effect
9 of 16
<PAGE> 10
on the Company's operations.
The Company believes that its cash and cash equivalents will be
sufficient to meet its operating expenses and cash requirements through 2000.
InSite Vision will require substantial additional funds prior to reaching
sustained profitability and the Company may seek private or public equity
investments, future collaborative agreements, and possibly research funding to
meet such needs. Even if the Company does not have an immediate need for
additional cash, it may seek access to the private or public equity markets if
and when it believes conditions are favorable. There is no assurance that such
additional funds will be available for the Company to finance its operations on
acceptable terms, or at all.
RISK FACTORS
IT IS DIFFICULT TO EVALUATE OUR BUSINESS BECAUSE WE ARE IN AN EARLY STAGE OF
DEVELOPMENT AND OUR TECHNOLOGY IS UNTESTED
We are in an early stage of developing our business. We are currently
only receiving a small amount of royalties from the sale of one of our products,
an over-the-counter, or OTC, dry eye treatment. Before regulatory authorities
will grant us marketing approval, we will need to conduct significant additional
research and development and preclinical and clinical testing. All of our
products are subject to risks that are inherent to products based upon new
technologies. These risks include the risks that our products:
- - will be found to be unsafe or ineffective;
- - will fail to receive necessary marketing clearance from regulatory
authorities;
- - even if safe and effective, will be too difficult to manufacture or
market;
- - will be unmarketable due to the proprietary rights of third parties; or
- - will not be able to compete with superior, equivalent or more
cost-effective products offered by competitors.
Therefore, we cannot guarantee that our research and development activities will
result in any commercially viable products.
WE WILL REQUIRE SIGNIFICANT ADDITIONAL FUNDING FOR OUR CAPITAL REQUIREMENTS
We will require substantial additional funding to develop and conduct
testing on our potential products. We will also require additional funding to
manufacture and market any products which we do develop. Our future capital
requirements will depend upon many factors, including:
- - the progress of our research and development programs;
- - the progress of preclinical and clinical testing;
- - our ability to establish additional corporate partnerships to develop,
manufacture and market our potential products;
- - the time and cost involved in obtaining regulatory approvals;
- - the cost of filing, prosecuting, defending and enforcing patent claims
and other intellectual property rights;
- - competing technological and market developments;
- - changes in our existing collaborative and licensing relationships; and
- - the purchase of additional capital equipment.
In addition, as part of the ISV-900 licensing activities, we received a
$5 million up front licensing fee from P&U. The UC Regents have alleged that
they are entitled to receive up to $2.5 million of this payment under the terms
of the August 1994 license agreement between us and the UC Regents. We dispute
this allegation and the parties are currently discussing a resolution to this
conflict. We cannot assure you that we will be able to settle this dispute on
acceptable terms or at all and our failure to prevail in this negotiation could
significantly increase our future capital requirements and could significantly
harm our business and financial condition. In addition, any litigation that
results from this dispute, even if successful, could result in substantial cost
to, and diversion of effort by, us and could harm our business and financial
condition.
We are currently seeking additional funding through public or private
equity or debt financing, collaborative or other arrangements, and from other
sources. We cannot be certain that we will be able to secure additional funding
from
10 of 16
<PAGE> 11
these sources, or that such funding will be on terms acceptable to us. If we
fail to secure additional funding upon acceptable terms, our business will be
harmed.
If we raise additional funds by issuing equity securities, our
stockholders will suffer substantial dilution. However, if we cannot raise
additional funding, we may be required to delay, scale back or eliminate one or
more of our research, discovery or development programs, or scale back or cease
operations altogether. In addition, the failure to raise additional funding may
force us to enter into agreements with third parties on terms which are
disadvantageous to us, which may, among other things, require us to relinquish
rights to our technologies, products or potential products.
WE MAY CONTINUE TO INCUR LOSSES
We have incurred significant operating losses since our inception in
1986. As of March 31, 2000, our accumulated deficit was approximately $85.5
million. Although we achieved profitability in 1999, we expect to incur net
losses for the foreseeable future or until we are able to achieve significant
royalties from sales of our licensed products.
Our ability to achieve significant revenue or profitability depends upon
our ability, alone or with third parties, to successfully develop our potential
products, conduct clinical trials, obtain required regulatory approvals and
successfully manufacture and market our products. We cannot be certain that we
will ever achieve or be able to maintain significant revenue or profitability.
WE RELY ON THIRD PARTIES TO DEVELOP, MARKET AND SELL OUR PRODUCTS
We have not established a dedicated sales and marketing organization.
Therefore, if we are to successfully commercialize our product candidates, we
will be required to enter into arrangements with one or more third parties that
will:
- - provide for Phase III clinical testing;
- - provide for commercial scale up and manufacture of our potential
products;
- - obtain or assist us in other activities associated with obtaining
regulatory approvals for our product candidates; and
- - market and sell our products, if they are approved.
There can be no assurance that we will be able to enter into such
arrangements on acceptable terms, if at all. If we are not successful in
concluding such arrangements, we may be required to establish our own sales and
marketing organization, although we have no experience in sales, marketing or
distribution. We cannot be certain we would be able to build such a marketing
staff or sales force, or that our sales and marketing efforts will be
cost-effective or successful.
Our strategy for research, development and commercialization of certain
of our products requires us to enter into various arrangements with corporate
and academic collaborators, licensors, licensees and others. Furthermore, we are
dependent on the diligent efforts and subsequent success of these outside
parties in performing their responsibilities.
We are dependent upon British Biotech for the supply of batimastat, the
active drugs incorporated into the Company's ISV-615 product candidate. British
Biotech has discontinued clinical testing of batimastat and informed us that it
will no longer manufacture the product. The Company and British Biotech are in
negotiations on a new licensing agreement related to batimastat that provides
for continued supply of the drug. If our licensing efforts are unsuccessful we
may have no source of ongoing raw materials for ISV-615. If this turns out to be
true, our business may be harmed.
We cannot be certain that, even if regulatory approvals are obtained,
our products will be marketed diligently or successfully by our partners, or
that we will be able to conclude arrangements with other companies to support
the commercialization of other products on acceptable terms, if at all.
In addition, we cannot be certain our collaborators will not take the
position that they are free to compete using our technology without compensating
or entering into agreements with us. Furthermore, we cannot be certain our
collaborators will not pursue alternative technologies or develop alternative
products either on their own or in collaboration with others, including our
competitors, as a means for developing treatments for the diseases or disorders
targeted by these collaborative programs.
11 of 16
<PAGE> 12
We plan to market and sell products through arrangements with third
parties with expertise in the ophthalmic drug or diagnostic industries. There
can be no assurance that we will be able to enter into such arrangements on
acceptable terms, if at all. If we are not successful in concluding such
arrangements, we may be required to establish our own sales and marketing
organization, although we have no experience in sales, marketing or
distribution. We cannot be certain we would be able to build such a marketing
staff or sales force, or that our sales and marketing efforts will be
cost-effective or successful. To the extent we have entered into or will enter
into co-marketing, co-promotion or other licensing arrangements for the
marketing and sale of our products, any revenues received by us will be
dependent on the efforts of third parties, such as CIBA Vision, Pharmacia and
B&L. We cannot be certain that these partners will diligently or successfully
market our products or that such efforts will be successful.
OUR BUSINESS DEPENDS UPON OUR PROPRIETARY RIGHTS, AND THERE IS A RISK OF
INFRINGEMENT
Our success will depend in large part on our ability to obtain patents,
protect trade secrets, obtain and maintain rights to technology developed by
others, and operate without infringing upon the proprietary rights of others. A
substantial number of patents in the field of ophthalmology and genetics have
been issued to pharmaceutical, biotechnology and biopharmaceutical companies.
Moreover, competitors may have filed patent applications, may have been issued
patents or may obtain additional patents and proprietary rights relating to
products or processes competitive with ours. We cannot be certain that our
patent applications will be approved, that we will develop additional
proprietary products that are patentable, that any issued patents will provide
us with adequate protection for our inventions or will not be challenged by
others, or that the patents of others will not impair our ability to
commercialize our products. The patent positions of firms in the pharmaceutical
and genetic industries generally are highly uncertain, involve complex legal and
factual questions, and have recently been the subject of much litigation. No
consistent policy has emerged from the U.S. Patent and Trademark Office or the
courts regarding the breadth of claims allowed or the degree of protection
afforded under pharmaceutical and genetic patents. Despite our efforts to
protect our proprietary rights, we cannot be certain others will not
independently develop similar products, duplicate any of our products or design
around any of our patents or that third parties from which we have licensed or
otherwise obtained technology will not attempt to terminate or scale back our
rights.
A number of pharmaceutical and biotechnology companies and research and
academic institutions have developed technologies, filed patent applications or
received patents on various technologies that may be related to our business.
Some of these technologies, applications or patents may conflict with our
technologies or patent applications. Such conflicts could limit the scope of the
patents, if any, we may be able to obtain or result in the denial of our patent
applications. In addition, if patents that cover our activities have been or are
issued to other companies, there can be no assurance that we will be able to
obtain licenses to these patents, at all, or at a reasonable cost, or be able to
develop or obtain alternative technology. If we do not obtain such licenses, we
could encounter delays or be precluded from introducing products to the market.
Litigation may be necessary to defend against or assert claims of
infringement, to enforce patents issued to us or to protect trade secrets or
know-how owned or licensed by us. Such litigation could result in substantial
cost to and diversion of effort by the Company, all of which may harm our
business. We have also agreed to indemnify our licensees, including Pharmacia,
against infringement claims by third parties related to our technology, which
could result in additional litigation costs and liability, which could harm our
business. In addition, we cannot be certain our efforts to protect or defend our
proprietary rights will be successful or, even if successful, will not result in
substantial cost to us.
We also depend upon unpatented trade secrets to maintain our competitive
position. We cannot be certain others will not independently develop
substantially equivalent proprietary information and techniques or otherwise
gain access to our trade secrets, that such trade secrets will not be disclosed
or that we can effectively protect our rights to unpatented trade secrets. To
the extent that we or our consultants or research collaborators use intellectual
property owned by others in their work for us, disputes also may arise as to the
rights in related or resulting know-how and inventions.
ACQUISITIONS MAY PRESENT RISKS TO OUR BUSINESS
At some point in the future, we may pursue acquisitions of companies,
product lines, technologies or businesses that our management believes are
complementary or otherwise beneficial to our Company. In the event that such an
acquisition does occur, we cannot be certain how such acquisitions will affect
our business. Future acquisitions may result in substantial dilution to our
stockholders, the incurrence of additional debt and amortization expenses
related to goodwill, research and development and other intangible assets, all
of which could harm our business. In addition, acquisitions would involve
several risks for us, including:
- - assimilating employees, operations, technologies and products from the
acquired companies with our existing
12 of 16
<PAGE> 13
employees, operation, technologies and products;
- - diverting our management's attention from day-to-day operation of our
business;
- - entering markets in which we have no or limited direct experience; and
- - potentially losing key employees from the acquired companies.
WE HAVE NO EXPERIENCE IN COMMERCIAL MANUFACTURING AND WE RELY ON A SOLE SOURCE
FOR CERTAIN RAW MATERIALS
We have no experience manufacturing products for commercial purposes. We
have a pilot facility licensed by the State of California to manufacture certain
of our products for Phase I and Phase II clinical trials. In July 1999, we
terminated our alliance under which B&L agreed to manufacture our products.
Should we encounter delays or difficulties in establishing and maintaining a
relationship with other qualified manufacturers to produce, package and
distribute our finished products, then clinical trials, regulatory filings,
market introduction and subsequent sales of our products will be harmed.
Contract manufacturers must adhere to Good Manufacturing Practices, or
GMP, regulations which are strictly enforced by the FDA on an ongoing basis
through its facilities inspection program. Contract manufacturing facilities
must pass a pre-approval plant inspection before the FDA will approve an New
Drug Application (NDA). Certain material manufacturing changes that occur after
approval are also subject to FDA review and clearance or approval. We cannot be
certain the FDA or other regulatory agencies will approve the process or the
facilities by which any of our products may be manufactured. Our dependence on
third parties for manufacture of products may harm our ability to develop and
deliver products on a timely and competitive basis. Should we be required to
manufacture products ourselves, we:
- - will be required to expend significant amounts of capital to install a
manufacturing capability;
- - will be subject to the regulatory requirements described above;
- - will be subject to similar risks regarding delays or difficulties
encountered in manufacturing any such products; and
- - will require substantial additional capital.
We cannot be certain we will be able to manufacture any products
successfully or in a cost-effective manner. In addition, certain of the raw
materials we use in formulating our DuraSite drug delivery system are available
from only one source. Any significant interruption in the supply of these raw
materials could delay our clinical trials, product development or product sales
and could harm our business.
OUR PRODUCTS ARE SUBJECT TO GOVERNMENT REGULATIONS AND APPROVAL
FDA and comparable agencies in state and local jurisdictions and in
foreign countries impose substantial requirements upon preclinical and clinical
testing, manufacturing and marketing of pharmaceutical products. Lengthy and
detailed preclinical and clinical testing, validation of manufacturing and
quality control processes, and other costly and time-consuming procedures are
required. Satisfaction of these requirements typically takes several years and
the time needed to satisfy them may vary substantially, based on the type,
complexity and novelty of the pharmaceutical product. The effect of government
regulation may be to delay or to prevent marketing of potential products for a
considerable period of time and to impose costly procedures upon our activities.
We cannot be certain the FDA or any other regulatory agency will grant approval
for any products we develop on a timely basis, or at all. Success in preclinical
or early stage clinical trials does not assure success in later stage clinical
trials. Data obtained from preclinical and clinical activities are susceptible
to varying interpretations that could delay, limit or prevent regulatory
approval. If regulatory approval of a product is granted, such approval may
impose limitations on the indicated uses for which a product may be marketed.
Further, even after we have obtained regulatory approval, later discovery of
previously unknown problems with a product may result in restrictions on the
product, including withdrawal of the product from the market. Moreover, the FDA
has recently reduced previous restrictions on the marketing, sale and
prescription of products for indications other than those specifically approved
by the FDA. Accordingly, even if we receive FDA approval of a product for
certain indicated uses, our competitors, including our collaborators, could
market products for such indications even if such products have not been
specifically approved for such indications. Delay in obtaining or failure to
obtain regulatory approvals would harm our business.
The FDA's policies may change and additional government regulations may
be promulgated which could prevent or delay regulatory approval of our potential
products. Moreover, increased attention to the containment of health care costs
in the U.S. could result in new government regulations that could harm our
business. We cannot predict the likelihood of adverse governmental regulation
that might arise from future legislative or administrative action, either in the
U.S. or abroad. See "Risk Factors -- We face risks from the uncertainties of
pricing and other regulation".
13 of 16
<PAGE> 14
WE COMPETE IN HIGHLY COMPETITIVE MARKETS
Our success depends upon developing and maintaining a competitive
position in the development of products and technologies in our areas of focus.
We have many competitors in the U.S. and abroad, including pharmaceutical,
biotechnology and other companies with varying resources and degrees of
concentration in the ophthalmic market. Our competitors may have existing
products or products under development which may be technically superior to ours
or which may be less costly or more acceptable to the market. Competition from
such companies is intense and expected to increase as new products enter the
market and new technologies become available. Many of our competitors have
substantially greater financial, technical, marketing, manufacturing and human
resources. In addition, they may also succeed in developing technologies and
products that are more effective, safer, less expensive or otherwise more
commercially acceptable than any which we have or will develop. Our competitors
may obtain cost advantages, patent protection or other intellectual property
rights that would block or limit our ability to develop our potential products,
or may obtain regulatory approval for commercialization of their products more
effectively or rapidly than we will. To the extent we decide to manufacture and
market our products by ourselves, we will also compete with respect to
manufacturing efficiency and marketing capabilities, areas in which we have
limited or no experience.
WE ARE DEPENDENT UPON KEY EMPLOYEES
We are highly dependent on Dr. Chandrasekaran and other principal
members of our scientific and management staff, the loss of whose services might
significantly delay the achievement of planned development objectives.
Furthermore, recruiting and retaining qualified personnel will be critical to
our success. Competition for skilled individuals in the biotechnology business
is highly intense, and we cannot be certain we will be able to continue to
attract and retain personnel necessary for the development of our business. The
loss of key personnel or the failure to recruit additional personnel or to
develop needed expertise could harm our business.
OUR INSURANCE COVERAGE MAY NOT ADEQUATELY COVER OUR POTENTIAL PRODUCT LIABILITY
EXPOSURE
We are exposed to potential product liability risks inherent in the
development, testing, manufacturing, marketing and sale of human therapeutic
products. Product liability insurance for the pharmaceutical industry is
generally expensive. We cannot be certain that our present product liability
insurance coverage is adequate. Such existing coverage will not be adequate as
we further develop our products, and we cannot be certain that adequate
insurance coverage against potential claims will be available in sufficient
amounts or at a reasonable cost.
WE FACE RISKS FROM THE UNCERTAINTIES OF PRICING AND OTHER REGULATION
Our business may be harmed by the continuing efforts of governmental and
third party payers to contain or reduce the costs of health care through various
means. For example, in certain foreign markets the pricing or profitability of
health care products is subject to government control. In the U.S., there have
been, and we expect there will continue to be, a number of federal and state
proposals to implement similar government control. While we cannot predict
whether any such legislative or regulatory proposals or reforms will be adopted,
the announcement of such proposals or reforms could harm our business, including
our ability to raise capital or form collaborations. The adoption of such
proposals or reforms could further harm our business.
In addition, in the U.S. and elsewhere, sales of health care products
are dependent in part on the availability of reimbursement from third party
payers, such as government and private insurance plans. Significant uncertainty
exists as to the reimbursement status of newly approved health care products,
and third party payers are increasingly challenging the prices charged for
medical products and services. If we succeed in bringing one or more products to
the market, we cannot be certain that reimbursement from third party payers will
be available or will be sufficient to allow us to sell our products on a
competitive or profitable basis.
WE USE HAZARDOUS MATERIALS WHICH MAY POSE ENVIRONMENTAL RISKS
Our research, development and manufacturing processes involve the
controlled use of small amounts of radioactive and other hazardous materials. We
are subject to federal, state and local laws, regulations and policies governing
the use, manufacture, storage, handling and disposal of such materials and
certain waste products. Although we believe that our safety procedures for
handling and disposing of such materials comply with the standards prescribed by
laws and regulations, we cannot completely eliminate the risk of accidental
contamination or injury from these materials. In the event of such an accident,
we could be held liable for any damages that result, and any such liability
could exceed our resources. Moreover, we may be required to incur significant
costs to comply with environmental laws and regulations, especially to
14 of 16
<PAGE> 15
the extent that we manufacture our own products.
OUR OFFICERS AND DIRECTORS WILL BE ABLE TO EXERT SIGNIFICANT CONTROL ON INSITE
As of March 31, 2000, our management and principal stockholders together
beneficially owned approximately 19% of our outstanding shares of common stock.
As a result, these stockholders, acting together, may be able to effectively
control all matters requiring approval by our stockholders, including the
election of a majority of our directors and the approval of business
combinations.
THE PRICE OF OUR COMMON STOCK IS VOLATILE
The market prices for securities of biopharmaceutical and biotechnology
companies, including ours, have been highly volatile, and the market has from
time to time experienced significant price and volume fluctuations that are
unrelated to the operating performance of particular companies. In addition,
future announcements concerning InSite, our competitors or other
biopharmaceutical companies, including the results of testing and clinical
trials, technological innovations or new therapeutic products, governmental
regulation, developments in patent or other proprietary rights, litigation or
public concern as to the safety of products developed by us or others and
general market conditions, may have a significant effect on the market price of
our common stock. We have not paid any cash dividends on our common stock, and
we do not anticipate paying any dividends in the foreseeable future.
WE HAVE ADOPTED CERTAIN ANTI-TAKEOVER PROVISIONS
Certain provisions of our certificate of incorporation and bylaws may
have the effect of making it more difficult for a third party to acquire, or
discouraging a third party from attempting to acquire, control of InSite. Such
provisions could limit the price that certain investors might be willing to pay
in the future for shares of our common stock. The board of directors has the
authority to issue up to 5,000,000 shares of preferred stock, 7,070 of which
have been designated as Series A Convertible Redeemable Preferred Stock.
Furthermore, the board of directors has the authority to determine the price,
rights, preferences, privileges and restrictions of the remaining unissued
shares of preferred stock without any further vote or action by the
stockholders. The rights of the holders of common stock will be subject to, and
may be adversely affected by, the rights of the holders of any preferred shares
and of preferred stock that may be issued in the future. The issuance of
preferred stock, while providing desirable flexibility in connection with
possible acquisitions and other corporate purposes, could have the effect of
making it more difficult for a third party to acquire a majority of our
outstanding voting stock. Certain provisions of Delaware law applicable to us
could also delay or make more difficult a merger, tender offer or proxy contest
involving us, including Section 203 of the Delaware General Corporation Law,
which prohibits a Delaware corporation from engaging in any business combination
with any interested stockholder for a period of three years unless certain
conditions are met.
WE HAVE CONVERTIBLE, REDEEMABLE SECURITIES THAT MAY RESULT IN DILUTION FOR
COMMON STOCKHOLDERS
Sales of shares of common stock issuable upon conversion of our Series A
Convertible Redeemable Preferred Stock could adversely affect the market value
of the common stock, depending upon the timing of such sales, and may effect a
dilution of the book value per share of our common stock.
As of March 31, 2000, warrants for 70 shares of Series A Convertible
Redeemable Preferred Stock were issued and outstanding. The actual number of
shares of common stock issuable upon exercise and conversion of the warrants for
outstanding Series A Convertible Redeemable Preferred Stock will equal:
(i) the aggregate stated value of the Series A Convertible
Redeemable Preferred Stock then being converted ($1,000 per share) plus
a premium in the amount of 6% per annum accruing from September 12, 1997
through the date of conversion, divided by
(ii) a conversion price equal to the lower of $2.127 or the
product of the average of the lowest closing bid prices for our common
stock for any 5 trading days during the 22 consecutive trading day
period immediately preceding the date of conversion, subject to
adjustment in accordance with the terms of the Certificate of
Designations, Preferences and Rights for the Series A Convertible
Redeemable Preferred Stock, multiplied by a conversion percentage equal
to 82.5%.
For a complete description of the relative rights, preferences,
privileges, powers and restrictions of the Series A Convertible Redeemable
Preferred Stock, see the Certificate of Designations, Preferences and Rights
attached as Exhibit 4.1
15 of 16
<PAGE> 16
to the Registration Statement on Form S-3 filed with the Securities and Exchange
Commission on September 29, 1997. Depending on market conditions at the time of
conversion, the number of shares of common stock issuable could increase
significantly in the event of a decrease in the trading price of the common
stock. Investors in common stock could therefore experience a dilution upon
conversion of the Series A Convertible Redeemable Preferred Stock. In addition,
in the event that the holder of the warrant for Series A Convertible Redeemable
Preferred Stock is unable to convert any such securities into common stock, the
holder may cause us to redeem in cash any such Series A Convertible Redeemable
Preferred Stock that cannot be so converted. In the event that we fail to so
redeem such shares, the holder of the Series A Convertible Redeemable Preferred
Stock is entitled to additional remedies as set forth in the Certificate of
Designations, Preferences and Rights.
PART II OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
a) Exhibits
27 Financial Data Schedule
b) No reports on Form 8-K were filed during the quarter ended March 31,
2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INSITE VISION INCORPORATED
Dated: May 15, 2000 by: /s/ S. Kumar Chandrasekaran
-----------------------------
S. Kumar Chandrasekaran, Ph.D.
Chairman of the Board,
Chief Executive Officer and
Chief Financial Officer
(on behalf of the registrant and as principal
financial and accounting officer)
16 of 16
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-END> MAR-31-2000
<CASH> 9,332
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 10,328
<PP&E> 294
<DEPRECIATION> 109
<TOTAL-ASSETS> 10,513
<CURRENT-LIABILITIES> 2,740
<BONDS> 0
0
31
<COMMON> 211
<OTHER-SE> 7,500
<TOTAL-LIABILITY-AND-EQUITY> 10,513
<SALES> 0
<TOTAL-REVENUES> 6
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 821
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (733)
<INCOME-TAX> 0
<INCOME-CONTINUING> (733)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (733)
<EPS-BASIC> (0.03)
<EPS-DILUTED> (0.03)
</TABLE>
